CAR-T Advancements Will Expand Global Cancer Therapy Access

Key Takeaways

• Rapid adoption and strong clinical data position CARVYKTI for accelerated growth, with potential to exceed conservative market expectations and drive sustained topline momentum.
  
• Pipeline diversity, manufacturing expansions, and favorable policy shifts could unlock multi-segment revenue, margin expansion, and stronger international presence.
  
• Heavy reliance on a single therapy, rising competition, high R&D costs, partnership limitations, and global pricing pressures threaten profitability and future growth.

Catalysts

Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.

• Analyst consensus expects substantial growth for CARVYKTI as it moves into earlier lines and frontline multiple myeloma settings, but these projections may be too conservative given the rapid 136% year-over-year sales growth, accelerating community adoption, and record-breaking uptake, suggesting the eligible patient pool and revenue ramp could outpace current forecasts.
  
• While analysts broadly agree on significant international expansion potential, current numbers may understate how the ongoing doubling of new ex-US launches and imminent manufacturing capacity expansions (Raritan and Tech Lane sites) could drive a step-change in global revenue and materially boost gross and net margins as operational leverage kicks in.
  
• Unprecedented long-term survival data for CARVYKTI-where one-third of heavily pretreated patients remain alive and progression-free after 5 years-combined with a dramatically improved outpatient safety profile is creating viral patient and physician awareness, likely to accelerate patient-driven demand and top-line growth far beyond gradual adoption curves.
  
• A robust and diversified innovation pipeline, including first-in-class solid tumor CAR-Ts, the TaVec off-the-shelf platform, and multiple next-gen autologous/in vivo assets, positions Legend not just to capture long-term oncology growth driven by the aging global population and rising cancer prevalence, but also to drive sustainable multi-segment revenue streams and margin expansion.
  
• Advances in healthcare policy-from broad regulatory streamlining to state-level removal of accreditation barriers-are enabling access to new community markets and regional hospital networks at an accelerating rate, unlocking new patient populations for CARVYKTI and future pipeline assets, and providing powerful, sustained tailwinds to revenue, market share, and operating leverage.

Legend Biotech Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more optimistic perspective on Legend Biotech compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• The bullish analysts are assuming Legend Biotech's revenue will grow by 38.6% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from -28.8% today to 31.8% in 3 years time.
• The bullish analysts expect earnings to reach $869.2 million (and earnings per share of $2.2) by about May 2029, up from -$296.8 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $73.2 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 22.9x on those 2029 earnings, up from -14.7x today. This future PE is greater than the current PE for the US Biotechs industry at 17.3x.
• The bullish analysts expect the number of shares outstanding to grow by 0.5% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.3%, as per the Simply Wall St company report.

Risks

• Heavy dependence on the CARVYKTI CAR-T therapy creates significant revenue concentration risk; if new competitive therapies or scientific setbacks emerge, this could lead to abrupt declines in product sales and increased earnings volatility.
  
• Intensifying competition in the cell therapy and myeloma treatment markets, with emerging bispecifics and next-generation CAR-Ts, threatens to erode Legend's pricing power and market share, thereby compromising future revenue growth and gross margins.
  
• Substantial and ongoing R&D spending, combined with the need to fund broad pipeline studies and new manufacturing expansions while relying on uncertain pipeline progress, puts sustained pressure on net margins and may delay achieving positive cash flow even as sales grow.
  
• Reliance on external commercialization and revenue-sharing partnerships, specifically with Janssen (Johnson & Johnson), limits Legend's operating leverage and ability to improve margins, constraining the scalability of profitability as topline revenues rise.
  
• Heightened pricing pressure and reimbursement scrutiny from government payors and insurers-particularly for high-cost, novel therapies like CAR-T-could restrict Legend's addressable market and slow revenue expansion, especially as the company grows its presence in Europe and other ex-US markets where price controls are common.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Legend Biotech is $86.0, which represents up to two standard deviations above the consensus price target of $57.23. This valuation is based on what can be assumed as the expectations of Legend Biotech's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $86.0, and the most bearish reporting a price target of just $21.0.
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $2.7 billion, earnings will come to $869.2 million, and it would be trading on a PE ratio of 22.9x, assuming you use a discount rate of 7.3%.
• Given the current share price of $23.59, the analyst price target of $86.0 is 72.6% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.